PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER).

How it works

Prismasol B22GK 2/0 is a solution used in continuous renal replacement therapy (CRRT) to correct electrolyte imbalances and remove waste products. It provides bicarbonate as a buffer via metabolism of lactate or acetate, and contains electrolytes to maintain homeostasis.

What the body does with it

Metabolism	Lactate is metabolized to bicarbonate primarily in the liver via gluconeogenesis and the Cori cycle; acetate is metabolized in peripheral tissues.
Excretion	Renal (100%); eliminated unchanged by ultrafiltration and diffusion during continuous renal replacement therapy (CRRT). Biliary/fecal: negligible.
Half-life	Not applicable; PRISMASOL B22GK 2/0 is a dialysate solution for CRRT. Components (glucose, electrolytes, lactate/bicarbonate) are continuously removed and replaced. For buffer conversion: lactate half-life ~5 minutes (hepatic metabolism to bicarbonate).
Protein binding	Negligible (<5%) for all components (glucose, ions, lactate, bicarbonate).
Volume of Distribution	Not applicable as the drug is a dialysate. Components distribute throughout extracellular fluid (Vd ~0.2 L/kg for sodium/chloride, ~0.5 L/kg for glucose).
Bioavailability	Intravenous (via CRRT circuit): 100% bioavailable. No oral or other routes relevant.
Onset of Action	Immediate upon initiation of CRRT; correction of electrolyte and acid-base disturbances begins within minutes.
Duration of Action	Duration matches the CRRT session (typically 24 hours continuous). Effects persist as long as therapy continues; no residual effect after termination.

Classification & Brands

Dosing & administration

Continuous renal replacement therapy (CRRT): prescription as per institutional protocol, typically 2000-2500 mL/h effluent rate (dialysate + replacement fluid) for adults. Peritoneal dialysis: 2-3 L exchanges, 4-5 times daily or cycler. Intravenous infusion only via CRRT or as dialysate/replacement fluid.

Dosage form	INJECTABLE
Renal impairment	Not applicable; drug is specifically designed for use in renal replacement therapy. For patients not on dialysis, use not indicated.
Liver impairment	No specific Child-Pugh adjustments; use standard dosing as per renal replacement prescription. Monitor electrolytes and acid-base status closely.
Pediatric use	CRRT: dose typically 2000-3000 mL/1.73 m²/h (effluent rate). Peritoneal dialysis: 30-50 mL/kg/exchange, 4-5 exchanges daily or cycler. Adjust based on clinical and laboratory parameters.
Geriatric use	Standard CRRT and peritoneal dialysis doses as per protocol; monitor fluid and electrolyte balance closely due to higher risk of complications. No specific dose adjustment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER).

Breastfeeding	Breastfeeding is considered safe as components are endogenous. M/P ratio not applicable; no significant excretion into breast milk expected.
Teratogenic Risk	PRISMASOL B22GK 2/0 is a sterile hemodialysis solution containing electrolytes and glucose. No teratogenic risk is expected due to its composition of physiological substances. Fetal risks are minimal if maternal acid-base and electrolyte status are maintained. No trimester-specific risks identified.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hyperlactatemia (e.g., lactic acidosis) for lactate-based solutions","Hypersensitivity to any component","Uncorrected severe electrolyte abnormalities"]

Clinical Precautions

Precautions

["Monitor electrolyte levels closely, especially potassium, calcium, magnesium, and phosphate","Adjust flow rates to avoid rapid shifts in fluid or electrolytes","Use caution in patients with severe liver disease or lactic acidosis as lactate metabolism may be impaired"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Lactate is metabolized to bicarbonate primarily in the liver via gluconeogenesis and the Cori cycle; acetate is metabolized in peripheral tissues.
Excretion	Renal (100%); eliminated unchanged by ultrafiltration and diffusion during continuous renal replacement therapy (CRRT). Biliary/fecal: negligible.
Half-life	Not applicable; PRISMASOL B22GK 2/0 is a dialysate solution for CRRT. Components (glucose, electrolytes, lactate/bicarbonate) are continuously removed and replaced. For buffer conversion: lactate half-life ~5 minutes (hepatic metabolism to bicarbonate).
Protein binding	Negligible (<5%) for all components (glucose, ions, lactate, bicarbonate).
Volume of Distribution	Not applicable as the drug is a dialysate. Components distribute throughout extracellular fluid (Vd ~0.2 L/kg for sodium/chloride, ~0.5 L/kg for glucose).
Bioavailability	Intravenous (via CRRT circuit): 100% bioavailable. No oral or other routes relevant.
Onset of Action	Immediate upon initiation of CRRT; correction of electrolyte and acid-base disturbances begins within minutes.
Duration of Action	Duration matches the CRRT session (typically 24 hours continuous). Effects persist as long as therapy continues; no residual effect after termination.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	Not applicable; drug is specifically designed for use in renal replacement therapy. For patients not on dialysis, use not indicated.
Liver impairment	No specific Child-Pugh adjustments; use standard dosing as per renal replacement prescription. Monitor electrolytes and acid-base status closely.
Pediatric use	CRRT: dose typically 2000-3000 mL/1.73 m²/h (effluent rate). Peritoneal dialysis: 30-50 mL/kg/exchange, 4-5 exchanges daily or cycler. Adjust based on clinical and laboratory parameters.
Geriatric use	Standard CRRT and peritoneal dialysis doses as per protocol; monitor fluid and electrolyte balance closely due to higher risk of complications. No specific dose adjustment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER (PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER).

Breastfeeding	Breastfeeding is considered safe as components are endogenous. M/P ratio not applicable; no significant excretion into breast milk expected.
Teratogenic Risk	PRISMASOL B22GK 2/0 is a sterile hemodialysis solution containing electrolytes and glucose. No teratogenic risk is expected due to its composition of physiological substances. Fetal risks are minimal if maternal acid-base and electrolyte status are maintained. No trimester-specific risks identified.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe hyperlactatemia (e.g., lactic acidosis) for lactate-based solutions","Hypersensitivity to any component","Uncorrected severe electrolyte abnormalities"]